Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- 22 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
- 12 Apr 2015 Planned End Date changed from 1 Jun 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.